N/A N=92 Long-Term Retention of Gadolinium in Bone
Focus: Long-term Retention of Gadolinium-based Contrast Agent
Primary: Concentration of Total Gadolinium in Trabecular Bone — 0.335; 0.783; 0; 0 micrograms/gram
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
Phase 4 N=357 Primovist / Eovist in Renally Impaired Patients
Contrast Media
Primary: Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and…
Phase 2 N=57 Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Central Nervous System Pathology
Primary: Overall Diagnostic Preference — 10; 34; 56; 26 Percentage of participants — p=<0.0001
N/A N=10 Renal Retention of Microbubbles
- Study Focus: Renal Retention of Lipid Microbubbles
Primary: Renal Video Intensity Units — 19 units on a scale
Phase 2 N=280 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Contrast to Noise Ratio (CNR) Difference — -10.59; 2.18; 8.66; 14.45 Ratio — p=0.1858
Phase 3 N=315 Gadobutrol Enhanced MRA of the Renal Arteries
Renal Artery Obstruction
Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.9; 77.6; 98.1; 81.7 Percentage of segments — p=<0.000
Phase 4 N=157 Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
Magnetic Resonance Imaging
Primary: Degree of Lesion Contrast Enhancement — 0.884; 0.863; 3.007; 2.979 Scores on a scale — p=< 0.0001
Phase 4 N=17 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale
N/A N=540 Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration
Renal Insufficiency
Primary: Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem — 0 Participants
Phase 3 N=402 Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Diagnostic Imaging · Central Nervous System Diseases
Primary: Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic…
Phase 3 N=479 Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Carotid Stenosis
Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.0; 72.7; 88.2; 24.4 percentage of segments — p=<0.0001
Phase 4 N=229 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 14; 7; 1; 171 participant exams — p=0.8516
Phase 1 N=140 A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
Magnetic Resonance Imaging
Primary: Plasma Clearance Estimates of Gadobutrol by Age Group — 2.07; 3.28; 4.90; 3.24 L/h
Phase 4 N=213 Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Chronic Kidney Disease · Renal Insufficiency
Primary: Capture of Post-marketing Safety Information in Patients With Moderate Renal Insufficiency Undergoing Routine Contrast-enhanced MRI With Administration of OMNISCAN in…
N/A N=20 Dispersal Pattern for Spine Injections (Gadolinium Contrast)
Cervical Radiculopathy
Primary: Injection Dispersal Patterns Measured (in cm) in the Superoinferior Directions on Post-injection MRI With a Calibrated Internal Measurement Software. — 14.73 cm
Phase 3 N=343 Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Central Nervous System Diseases
Primary: Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic…
N/A N=44,456 Post-marketing Surveillance Study for Evaluation of Dotarem Safety
Contrast-enhanced MRI With Dotarem
Primary: Frequency of Adverse Events — 225 adverse events
Phase 3 N=256 Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.90; 2.08; 3.64; 1.74 mean of a score (on a scale) per patient — p=<.0001
N/A N=168 Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Fibrosis · Kidney Failure · Renal Insufficiency
Primary: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and…
Phase 2 N=237 Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Brain Diseases · Spinal Cord Diseases
Primary: Categorical Visualization Score (CVS) — 1.43; 2.02; 1.98 Scores on a scale — p=0.003
N/A N=12 Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
Multiple Sclerosis
Primary: A Change in the Cumulative Number of Gd Enhancing Lesions Using a 3T Protocol. — -3.7; -3.6 GAD lesions (number of)
Phase 1 N=10 Safety and Dialysability of Dotarem® in Dialysed Patients
End-stage Renal Failure
Primary: Dialysability of Dotarem® in Dialysed Patients — -88.2; -93.4; -97.1; -94.8 percent change in Gd concentration
N/A N=513 Comparison of Contrast Agents During CT Angiography
Contrast Enhancement on Cardiac CT
Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units
Phase 3 N=165 SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Brain Metastases
Primary: Number of Lesions Detected by Blinded Readers (BR) and Investigator — 6.28; 6.92; 6.87; 6.36 lesions
Phase 1 N=44 Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
Magnetic Resonance Imaging
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Infinity of Gadobutrol: Individual — 776 micromole*h/L
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
Phase 2 N=80 Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI
Central Nervous System Indication · Pediatric Patients · Body Indication
Primary: Elimination Half-life — 1.29; 1.48; 1.77 hours
Phase 2 N=36 Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age
Central Nervous System Diseases · Pediatric Disorder · Body Indication
Primary: Area Under the Curve (AUCinf) — 392.3; 493.3 h.mg/L
N/A N=1,537 Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography
MR Mammography With Dotarem
Primary: Image Quality — 495; 898; 118; 8 Participants